Literature DB >> 26112906

SVVYGLR motif of the thrombin-cleaved N-terminal osteopontin fragment enhances the synthesis of collagen type III in myocardial fibrosis.

Ayako Uchinaka1, Yoshinosuke Hamada1, Seiji Mori2, Shigeru Miyagawa3, Atsuhiro Saito4, Yoshiki Sawa3, Nariaki Matsuura2, Hirofumi Yamamoto2, Naomasa Kawaguchi5.   

Abstract

Osteopontin (OPN) is involved in various physiological processes such as inflammatory and wound healing. However, little is known about the effects of OPN on these tissues. OPN is cleaved by thrombin, and cleavage of the N-terminal fragment exposes a SVVYGLR sequence on its C-terminus. In this study, we examined the effects of the thrombin-cleaved OPN fragments on fibroblasts and myocardial fibrosis, particularly the role of the SVVYGLR sequence. The recombinant thrombin-cleaved OPN fragments (N-terminal fragment [N-OPN], C-terminal fragment [C-OPN], and the N-terminal fragment lacking the SVVYGLR sequence [ΔSV N-OPN]) were added to fibroblasts, and the cellular motility, signal activity, and production of collagen were evaluated. A sustained-release gel containing an OPN fragment or SVVYGLR peptide was transplanted into a rat model of ischemic cardiomyopathy and the quantities and ratio of collagen type I (COL I) and type III (COL III) were estimated. N-OPN significantly promoted fibroblast migration. Smad signal activity, expression of smooth muscle actin (SMA), and the production of COL III were enhanced by N-OPN and SVVYGLR peptide. Conversely, ΔSV N-OPN and C-OPN had no effect. In vivo, the expression level of N-OPN was associated with COL III distribution, and the COL III/COL I ratio was significantly increased by the sustained-release gel containing N-OPN or SVVYGLR peptide. The cardiac function was also significantly improved by the N-OPN- or SVVYGLR peptide-released gel treatment. The N-terminal fragment of thrombin-cleaved OPN-induced Smad signal activation, SMA expression, and COL III production, and its SVVYGLR sequence influences this function.

Entities:  

Keywords:  Collagen type III; Fibrosis; Osteopontin; SVVYGLR peptide

Mesh:

Substances:

Year:  2015        PMID: 26112906     DOI: 10.1007/s11010-015-2495-y

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  40 in total

1.  The integrin alpha(9)beta(1) binds to a novel recognition sequence (SVVYGLR) in the thrombin-cleaved amino-terminal fragment of osteopontin.

Authors:  Y Yokosaki; N Matsuura; T Sasaki; I Murakami; H Schneider; S Higashiyama; Y Saitoh; M Yamakido; Y Taooka; D Sheppard
Journal:  J Biol Chem       Date:  1999-12-17       Impact factor: 5.157

2.  Synthetic osteopontin-derived peptide SVVYGLR can induce neovascularization in artificial bone marrow scaffold biomaterials.

Authors:  Yoshinosuke Hamada; Hiroshi Egusa; Yoshitosi Kaneda; Isao Hirata; Naomasa Kawaguchi; Takafumi Hirao; Takuya Matsumoto; Makiko Yao; Kiyoshi Daito; Mayuka Suzuki; Hirofumi Yatani; Michiharu Daito; Masayuki Okazaki; Nariaki Matsuura
Journal:  Dent Mater J       Date:  2007-07       Impact factor: 2.102

3.  Enhanced bone regeneration via multimodal actions of synthetic peptide SVVYGLR on osteoprogenitors and osteoclasts.

Authors:  Hiroshi Egusa; Yoshitoshi Kaneda; Yoshihiro Akashi; Yoshinosuke Hamada; Takuya Matsumoto; Makio Saeki; Devang K Thakor; Yasuhiko Tabata; Nariaki Matsuura; Hirofumi Yatani
Journal:  Biomaterials       Date:  2009-06-10       Impact factor: 12.479

4.  Collagen remodeling and cardiac dysfunction in patients with hypertrophic cardiomyopathy: the significance of type III and VI collagens.

Authors:  M Kitamura; M Shimizu; H Ino; K Okeie; M Yamaguchi; N Funjno; H Mabuchi; I Nakanishi
Journal:  Clin Cardiol       Date:  2001-04       Impact factor: 2.882

5.  Dilated cardiomyopathy is associated with significant changes in collagen type I/III ratio.

Authors:  M Pauschinger; D Knopf; S Petschauer; A Doerner; W Poller; P L Schwimmbeck; U Kühl; H P Schultheiss
Journal:  Circulation       Date:  1999-06-01       Impact factor: 29.690

6.  Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin).

Authors:  R Agnihotri; H C Crawford; H Haro; L M Matrisian; M C Havrda; L Liaw
Journal:  J Biol Chem       Date:  2001-05-25       Impact factor: 5.157

7.  Enhanced deposition of predominantly type I collagen in myocardial disease.

Authors:  J E Bishop; R Greenbaum; D G Gibson; M Yacoub; G J Laurent
Journal:  J Mol Cell Cardiol       Date:  1990-10       Impact factor: 5.000

8.  A regulated interaction between alpha5beta1 integrin and osteopontin.

Authors:  S T Barry; S B Ludbrook; E Murrison; C M Horgan
Journal:  Biochem Biophys Res Commun       Date:  2000-01-27       Impact factor: 3.575

9.  Collagen in dilated cardiomyopathy--scanning electron microscopic and immunohistochemical observations.

Authors:  H Yoshikane; M Honda; Y Goto; S Morioka; A Ooshima; K Moriyama
Journal:  Jpn Circ J       Date:  1992-09

10.  Up-regulation and profibrotic role of osteopontin in human idiopathic pulmonary fibrosis.

Authors:  Annie Pardo; Kevin Gibson; José Cisneros; Thomas J Richards; Yinke Yang; Carina Becerril; Samueal Yousem; Iliana Herrera; Victor Ruiz; Moisés Selman; Naftali Kaminski
Journal:  PLoS Med       Date:  2005-09-06       Impact factor: 11.069

View more
  7 in total

1.  Angiotensin 1-7, but not the thrombin-cleaved osteopontin C-terminal fragment, attenuates osteopontin-mediated macrophage-induced endothelial-cell inflammation.

Authors:  Rachel Hamias; Assaf Rudich; George Greenberg; Gabriel Szendro; Talya Wolak
Journal:  Inflamm Res       Date:  2017-11-27       Impact factor: 4.575

2.  Osteopontin in Vascular Disease.

Authors:  Zoe Shin Yee Lok; Alicia N Lyle
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

3.  Osteopontin Peptide Icosamer Containing RGD and SLAYGLR Motifs Enhances the Motility and Phagocytic Activity of Microglia.

Authors:  Il-Doo Kim; Hahnbie Lee; Yin-Chuan Jin; Ja-Kyeong Lee
Journal:  Exp Neurobiol       Date:  2017-12-11       Impact factor: 3.261

4.  Proangiogenic functions of an RGD-SLAY-containing osteopontin icosamer peptide in HUVECs and in the postischemic brain.

Authors:  Hahnbie Lee; Yin-Chuan Jin; Seung-Woo Kim; Il-Doo Kim; Hye-Kyung Lee; Ja-Kyeong Lee
Journal:  Exp Mol Med       Date:  2018-01-19       Impact factor: 8.718

5.  Thrombin cleavage of osteopontin controls activation of hepatic stellate cells and is essential for liver fibrogenesis.

Authors:  Guangying Cui; Jianing Chen; Zhongwen Wu; Haijun Huang; Lin Wang; Yan Liang; Ping Zeng; Jiezuan Yang; Toshimitsu Uede; Hongyan Diao
Journal:  J Cell Physiol       Date:  2018-10-23       Impact factor: 6.384

6.  Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin.

Authors:  Kate M Herum; Andreas Romaine; Ariel Wang; Arne Olav Melleby; Mari E Strand; Julian Pacheco; Bjørn Braathen; Pontus Dunér; Theis Tønnessen; Ida G Lunde; Ivar Sjaastad; Cord Brakebusch; Andrew D McCulloch; Maria F Gomez; Cathrine R Carlson; Geir Christensen
Journal:  J Am Heart Assoc       Date:  2020-01-31       Impact factor: 5.501

7.  Outcome in German and South African peripartum cardiomyopathy cohorts associates with medical therapy and fibrosis markers.

Authors:  Feriel Azibani; Tobias J Pfeffer; Melanie Ricke-Hoch; Wentzel Dowling; Stefan Pietzsch; Olivia Briton; Johann Baard; Valeska Abou Moulig; Tobias König; Dominik Berliner; Elena Libhaber; Stella Schlothauer; John Anthony; Ralf Lichtinghagen; Johann Bauersachs; Karen Sliwa; Denise Hilfiker-Kleiner
Journal:  ESC Heart Fail       Date:  2020-02-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.